Key facts
- This page summarizes Wellington Biomedical Innovation Master Investors (Cayman) II L.P.'s Form 4 filing for Metsera, Inc. (MTSR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Feb 2025, 18:48.
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. - 30 Jan 2025 Form 4 Insider Report for Metsera, Inc. (MTSR)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- MTSR
- Reported as of
- 30 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Feb 2025, 18:48:52 UTC
- Prior SEC filing
- 15 Oct 2024
- Next SEC filing
- 29 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- Wellington Biomedical Innovation Master Investors (Cayman) II L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter N. McIsaac, Authorized Person
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. filed Form 4 for Metsera, Inc. (MTSR) on 03 Feb 2025.
Change
- Previous filing in this sequence was filed on 15 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MTSR
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,857,699
- Change %
- Price
- Shares after
- 1,857,699
- Date
- 30 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MTSR
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -4,365,079
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 30 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,857,699
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Each share of Series B Preferred Stock automatically converted into Common Stock on a 2.349723-for-1 basis upon closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date.